[REVISION HISTORY]
Romania medication accessibility and supply shortages
Updated 1 time since CLSTR started tracking revisions of this situation.
What changed
2026-08-25 05:51 UTC → 2026-08-26 15:30 UTC ·
added
removed
Romanian Romania medication accessibility and supply shortages
In Romania, patient associations have issued an open letter to interim Prime Minister Ilie Bolojan regarding the accessibility of medications. The associations are responding to government suggestions to prioritize generic or biosimilar drugs over expensive innovative therapies to manage costs. They cautioned that focusing solely on cost comparisons without clinical analysis could be dangerous, noting that “a medication accessible only on paper treats no one.” Following these concerns, reports emerged of significant supply Supply discontinuities for critical medications. Shortages have been confirmed for cardiovascular treatments, such as metoprolol and metoprolol, carvedilol, and captopril, as well as oncology drugs like imatinib. Other affected areas include Shortages also affect neurological, psychiatric, diabetes, and Parkinson’s disease medications. While medications, including pregabalin, atomoxetine, and valproic acid. The College of Pharmacists Prahova noted that while some disruptions are considered temporary, officials indicated that supply for certain products may not resume until late between September and December 2026. Following reports from the Federation of Cancer Patient Associations (FABC) that three oncology drugs are missing from the market and eight others face repeated discontinuities, interim Health Minister Cseke Attila ordered an emergency audit. This audit will examine the National Agency for Medicines and Medical Devices (ANMDMR), the National Oncology Program, and hospital supply structures. The Minister emphasized the need for a digital system to track drug traceability and stock levels in real-time. The Romanian College of Physicians (CMR) warned that treatment delays can compromise therapeutic objectives, stating patients should not be forced to seek their own solutions. While the President of the National Health Insurance House (CNAS) stated there is no general crisis and that cytostatic stocks remain stable, he acknowledged that EU production deficiencies can cause localized shortages.
Versions
- 2026-08-26 15:30 UTC Romania medication accessibility and supply shortages
- 2026-08-25 05:51 UTC Romanian medication accessibility and supply shortages
Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.